Rheumatoid Arthritis Interstitial Lung Disease

Vinik, Ophir; Marras, Theodore K.; Shapera, Shane; Mittoo, Shikha

doi:10.5772/27626

Cited by 1 publication

(1 citation statement)

References 127 publications

(89 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These include the extent of honeycombing on HRCT imaging, decrease in diffusing capac ity of lung for carbon monoxide (D lco ), longitudinal decline in FVC or D lco , new onset of desaturation during exercise, presence of pulmonary hypertension, and level of dyspnea. 14,23,44,45 In clinically evident RA-ILD, there are emerging data to suggest that prognosis may also be related to the underlying histopathologic phenotype, with RA-ILD with UIP pattern having increased mortality compared with non-UIP. 36,[46][47][48][49][50][51] For example, patients with RA-ILD with UIP pattern have a lower median survival compared with patients with non-UIP pattern, and the HRCT scan pattern of UIP was independently associated with worse survival.…”

Section: Current State Of Knowledgementioning

confidence: 99%

A Roadmap to Promote Clinical and Translational Research in Rheumatoid Arthritis-Associated Interstitial Lung Disease

Doyle

Lee

Dellaripa

et al. 2014

Chest

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is a systemic inflammatory disorder affecting approximately 1.3 million adults in the United States. Approximately 10% of these individuals with RA have clinically evident interstitial lung disease (RA-ILD), and an additional one-third demonstrate subclinical ILD on chest CT scan. The risk of death for individuals with RA-ILD is three times higher than for patients with RA without ILD, with a median survival after ILD diagnosis of only 2.6 years. Despite the high prevalence and mortality of RA-ILD, little is known about its molecular features and its natural history. At present, we lack a standard validated approach to the definition, diagnosis, risk stratification, and management of RA-ILD. In this perspective, we discuss the importance of clinical and translational research and how ongoing research efforts can address important gaps in our knowledge over the next few years. Furthermore, recommendations are made to design multicenter collaborative studies that will expedite the development of clinical trials designed to decrease the significant morbidity and mortality associated with RA-ILD.

show abstract